ARS Pharmaceuticals Inc
Follow $SPRY
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $SPRY by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is SPRY moving today?
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
SPRY overview
Related filings and maps
Congress activity in SPRY
No receipt-qualified Congressional disclosure is present for SPRY in the cached public ledger.
SPRY contract awards, year to date.
Public federal awards linked to this ticker.
SPRY lobbying filings, year to date.
Registered lobbying filings matched to ARS Pharmaceuticals Inc.